In Israel, DayTwo, a leader in microbiome-health management, completed a $12.0 million Series A financing round to broaden and deepen its lead in evidence-based, clinically proven and actionable science of the gut microbiome. The investment made by Johnson & Johnson Innovation, Seventure Partners’ Health for Life Capital fund, Mayo Clinic, co-founder Marius Nacht and other private investors brings DayTwo’s total funding to $17.0 million.
DayTwo is the first company to develop a method to accurately predict an individual’s glycemic response to specific foods and food combinations using an individual’s microbiome and other clinical factors. This evidence-based approach to nutrition enables DayTwo to bring personalized nutrition to market and make personalized nutrition a reality for millions of people.
For consumers, DayTwo offers a cloud-based, proprietary diet and nutrition planner enabling individuals to get personalized scores for specific foods and food combinations based on their own gut-microbiome profile and other personal parameters.